Human embryonic stem cell technologies a
β
Janne Jensen; Johan Hyllner; Petter BjΓΆrquist
π
Article
π
2009
π
John Wiley and Sons
π
English
β 206 KB
## Abstract Development of new drugs is costly and takes huge resources into consideration. The big pharmaceutical companies are currently facing increasing developmental costs and a lower successβrate of bringing new compounds to the market. Therefore, it is now of outmost importance that the drug